But maximum dose comparison does not tell the whole story
[6] Galcanezumab was developed by Eli Lilly
Research Background GHK-Cu has been studied extensively in preclinical research for roles in tissue remodeling, collagen synthesis, antioxidant activity, and gene-expression modulation
This is not happening in the marketplace, because the current model benefits the middlemen, these pharmacy benefit managers and insurers for collecting all of these rebates and fees and pocketing them and therefore they really like covering brand name medicines with higher prices and high rebates and fees instead of lower cost alternatives like generics, authorized generics or biosimilars
Published scientific literature discusses GHK-Cu in relation to copper peptide research, peptide chemistry, gene expression studies, molecular biology, receptor biology, cellular communication, and analytical peptide characterization
Consult our wellness coach for tailored guidance on healthy lifestyle changes